Aditxt Inc Ordinary Shares ADTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ADTX is a good fit for your portfolio.
News
-
Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023
-
For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy
-
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023
-
Aditxt, Inc. Acquires Proprietary Electroencephalography (EEG) Brain Monitoring Technologies and Devices, Including NeuroCap™ and NeuroEEG™ for Telehealth and Tele-neurology Applications
-
Aditxt, Inc.’s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.’s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million
-
Aditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
-
Aditxt, Inc. Regains Compliance with Nasdaq Stockholders’ Equity Requirement
Trading Information
- Previous Close Price
- $2.96
- Day Range
- $3.04–3.46
- 52-Week Range
- $2.96–76.40
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $5.76 Mil
- Volume/Avg
- 367,464 / 663,959
Key Statistics
- Price/Earnings (Normalized)
- 7.77
- Price/Sales
- 0.65
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune™ and AditxtScore™. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures as these drugs prevent or delay organ rejection. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) which utilizes a tolerogenic approach that utilizes the body's natural process of cell death, to deliver a modified antigen that signals the immune system to become tolerant to transplanted tissues.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 61
- Website
- https://www.aditxt.com
Valuation
Metric
|
ADTX
|
---|---|
Price/Earnings (Normalized) | 7.77 |
Price/Book Value | — |
Price/Sales | 0.65 |
Price/Cash Flow | — |
Price/Earnings
ADTX
Financial Strength
Metric
|
ADTX
|
---|---|
Quick Ratio | 0.18 |
Current Ratio | 0.30 |
Interest Coverage | −7.92 |
Quick Ratio
ADTX
Profitability
Metric
|
ADTX
|
---|---|
Return on Assets (Normalized) | −261.75% |
Return on Equity (Normalized) | −1,406.21% |
Return on Invested Capital (Normalized) | −374.47% |
Return on Assets
ADTX
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Sgbgzfqjh | Dkljb | $570.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Fbzxjyfh | Czzpzz | $108.0 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Lrhxswzt | Mcmrt | $105.6 Bil | |
MRNA
| Moderna Inc | Xldsljsj | Blvg | $40.8 Bil | |
ARGX
| argenx SE ADR | Lrppjwd | Zvfn | $23.5 Bil | |
BNTX
| BioNTech SE ADR | Srndrbrpq | Zvqy | $21.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zyzsggkq | Jbqzlv | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Wffqpfr | Gsmrs | $16.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Yytbybmq | Fhrwnc | $13.6 Bil | |
INCY
| Incyte Corp | Cclpjyyq | Hkzjzqv | $12.8 Bil |